Welcome to PAREXEL on Policy (PoP), the leading source for health

policy and reimbursement information for the biopharmaceutical and

medical device industries.  PoP is a service of PAREXEL's Health

Policy and Strategic Reimbursement Team, which is based in our metropolitan Washington, DC office.

 

Check out our Parexel on Policy (PoP) Updates by clicking the

"PoP Updates" tab above.

 

***************************************************************************************


 

HEALTH POLICY AND STRATEGIC REIMBURSEMENT

As a new drug, biotechnology, or medical device product approaches market launch, its manufacturer must possess a clear, in-depth understanding of the public and private reimbursement environment that the product will face.

As the leader in developing solutions for complex health policy and reimbursement issues facing manufacturers, PAREXEL's Health Policy and Strategic Reimbursement Team provides our industry clients with a range of services to remove barriers to product acceptance, further appropriate patient access, and demonstrate a product’s value.  We also distill health policy developments into their essential elements and provide strategic recommendations to our clients on how broad healthcare issues will impact the industry

At PAREXEL we interact with key legislators, senior healthcare regulators, national association executives, and other public policy leaders to guide our clients through the complex and ever-changing healthcare landscape. Additionally, we work closely with PAREXEL’s co-located Reimbursement HELPlines, Patient Assistance Programs, and Phase IV Program Coordinating Centers to provide our clients a single point of contact for strategic health policy and reimbursement solutions. 

Our Reimbursement and Market Access services include:

  • Reimbursement and Market Access Strategy
  • Competitive Product Reimbursement Analysis
  • Payer Coverage Analysis
  • Analysis of Clinical Endpoints
  • Review of Patient Access Hurdles
  • Setting of Care Considerations and Associated Payment
    Values
  • Product Coding Requirements and Strategy Development
  • Evidence Based Medicine Development & Comparative
  • Effectiveness Research
  • Compendia Coverage Analysis
  • Development of an Optimal Label
    Optimal Clinical Trial Design
  • Patient Access and Reimbursement Support Programs

________________________________________

PAREXEL INTERNATIONAL CORPORATION

 

 

PAREXEL is a leading global biopharmaceutical services
company with over 10,000 employees in 52 countries,
providing a broad range of expertise in clinical research,
medical communications services, consulting, and
informatics and advanced technology products and
services to the worldwide pharmaceutical, biotechnology,
and medical device industries. Our primary objective is
to provide solutions for managing the biopharmaceutical
product lifecycle with the goal of reducing the time, risk,
and cost associated with the development and
commercialization of new therapies. Since our
incorporation in 1983, we have developed significant
expertise in processes and technologies supporting this
strategy.

 

For more information, please visit the PAREXEL Web site.

 _________________________

 


© Copyright 2004 PAREXEL International. All rights reserved.